Welcome to our dedicated page for Jasper Therapeutics SEC filings (Ticker: JSPRW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC filings for Jasper Therapeutics, Inc., whose redeemable warrants trade on Nasdaq under the symbol JSPRW and whose voting common stock trades under JSPR. These filings include current reports on Form 8-K, registration statements such as Form S-3, and other periodic reports that describe the company’s clinical-stage biotechnology activities and capital markets transactions.
In a Form 8-K, Jasper Therapeutics reported entering into an underwriting agreement for an underwritten public offering of common stock, pre-funded warrants and common warrants. The filing details the terms of the offering, including the relationship between the warrants and the company’s voting common stock, and identifies JSPRW as redeemable warrants, each ten of which are exercisable for one share of common stock at a specified exercise price. Such documents allow investors to review the structure of the company’s securities and the intended use of proceeds, including advancement of briquilimab programs in mast-cell driven diseases and general corporate purposes.
The same Form 8-K also contains an Item 8.01 corporate update on the BEACON study in Chronic Spontaneous Urticaria. Jasper Therapeutics describes its investigation into confounded efficacy results in certain cohorts, its review of drug substance and drug product manufacturing and distribution, and its focus on clinical site activity. Filings like this provide detailed context on the company’s clinical development work and how it evaluates trial data.
On Stock Titan, these SEC filings are available with AI-powered summaries that explain key terms and highlight important sections, helping readers interpret complex documents such as 8-Ks, registration statements and other reports. Users can review filings related to offerings, warrant structures, clinical study updates and risk disclosures, while AI tools assist in identifying the most relevant information for understanding Jasper Therapeutics’ activities and the characteristics of the JSPRW warrants.
Jasper Therapeutics reported its fourth quarter and full-year 2025 results and provided a corporate update focused on briquilimab, its antibody therapy for mast cell–driven diseases such as chronic urticaria and asthma. For 2025, operating expenses were $83.9 million, driven by $63.1 million in research and development and $20.8 million in general and administrative costs. Net loss for 2025 was $75.8 million compared with $71.3 million in 2024, reflecting continued investment in clinical programs. As of December 31, 2025, Jasper held $28.7 million in cash and cash equivalents, down from $71.6 million a year earlier, and reported total assets of $35.8 million and stockholders’ equity of $4.2 million. The company plans to begin enrolling patients in the Phase 2b portion of a planned Phase 2b/3 chronic spontaneous urticaria study in the second half of 2026, pending capital availability.
Jasper Therapeutics, Inc. files its annual report outlining progress on briquilimab, a monoclonal antibody targeting mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. The company highlights positive early-stage clinical data, a shift of resources away from stem cell transplant uses, and a strategy to build a focused mast cell therapeutics franchise.
Jasper holds worldwide rights to briquilimab under exclusive licenses from Amgen and Stanford, supported by patent families expected to expire in 2027 with newer applications potentially extending protection into the 2040s. The report also details regulatory pathways, manufacturing via Lonza, competitive landscape, and substantial ongoing funding needs with a history of operating losses and going-concern risk.
Jasper Therapeutics received an Amendment No. 4 to a Schedule 13D from a group of Carlyle- and Abingworth-affiliated entities updating their ownership in its voting common stock. The group reports beneficial ownership of 1,088,310 shares of common stock, representing 3.8% of the class, based on 27,984,039 shares outstanding as of November 6, 2025. The filing notes that, as of this amendment, the reporting persons have ceased to be beneficial owners of more than five percent of Jasper’s outstanding common stock and that they have not effected any transactions in the stock during the past 60 days. Voting and dispositive power over these shares is shared among the affiliated investment entities.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 1,764,848 shares of Jasper Therapeutics voting common stock, representing 6.3% of the class. They have shared voting and shared dispositive power over all of these shares, with no sole authority.
The firms state that the securities were acquired and are held in the ordinary course of business and not to change or influence control of Jasper Therapeutics. A joint filing agreement confirms that both entities are reporting together, with signatures provided by an attorney-in-fact dated January 6, 2026.
Morgan Stanley filed a Schedule 13G reporting a significant ownership position in Jasper Therapeutics, Inc. voting common stock. Morgan Stanley reports beneficial ownership of 1,969,785 shares, representing 7.0% of the class, with shared voting and shared dispositive power over these shares.
Affiliated entity Morgan Stanley Capital Services LLC reports beneficial ownership of 1,903,420 shares, or 6.8% of the class, also with shared voting and dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Jasper Therapeutics.
Jasper Therapeutics CEO and President Jeetinder Singh Mahal received a stock option covering 500,000 shares of voting common stock on February 6, 2026. The option has an exercise price of $1.35 per share and expires on February 6, 2036.
According to the vesting terms, one quarter of the option vests on February 6, 2027, with the remaining three quarters vesting in equal monthly installments over the following 36 months, conditioned on continued service with the company.
A shareholder group associated with Anders Hove filed an amended Schedule 13G reporting beneficial ownership of 1,486,492 shares of Jasper Therapeutics, Inc. common stock, equal to 5.3% of the class. This ownership is held through investment entities including Acorn Bioventures, L.P. and Acorn Bioventures 2, L.P., with related general partners Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC. The percentages are based on 27,984,039 shares of common stock outstanding as of November 6, 2025. The reporting persons certify the shares were not acquired and are not held for the purpose of changing or influencing control of Jasper Therapeutics.
Velan Capital and affiliated Avego entities report a joint Schedule 13D/A disclosing purchases in Jasper Therapeutics, Inc. The filing shows 27,889,950 Shares outstanding after the 2025 Offering. Velan Master directly owns 2,381,915 Shares (~8.5%), Velan Horizon owns 41,152 Shares (~0.1%), and Avego Fund owns 245,328 Shares (~0.9%). Aggregated beneficial ownership attributable to Velan Capital Investment Management LP and related entities is 2,668,395 Shares (~9.6%).
The filing discloses purchases made in a September 19, 2025 underwritten offering at $2.43 per unit, related acquisition costs for each purchaser, receipt of Warrants (Velan Master: 1,193,415; Velan Horizon: 41,152) exercisable after six months at $2.92 for four years, a customary 90-day lock-up with the underwriters, and a 9.99% beneficial ownership blocker on the Warrants.
Jasper Therapeutics, Inc. filed an 8-K reporting a material event that includes an Underwriting Agreement dated September 18, 2025 with TD Securities (USA) LLC and a set of exhibits: forms of pre-funded and common warrants, a legal opinion and consent from Paul Hastings LLP, a press release dated September 18, 2025, and an iXBRL cover page file. The filing also describes a comprehensive review and testing program for manufacturing and clinical supply lots, including robust lot testing, independent blinded testing of returned product samples, stability comparisons, and reviews of patient selection, investigational product handling, and drug delivery details. The form is signed by CFO Herb Cross on September 19, 2025. No offering terms, proceeds, or financial impacts are disclosed in the provided text.
Jasper Therapeutics is offering common stock, pre-funded warrants and common warrants to raise approximately $27.9 million in net proceeds, based on a public offering price of $2.43 per common share with an attached common warrant. The offering includes 12,345,707 common warrants (initial exercise price $2.92) and 675,000 pre-funded warrants. Shares outstanding rise from 16,219,243 to 27,889,950 assuming no warrant exercises. Net tangible book value per share was $1.45 as of June 30, 2025, estimated to increase by $0.39 to $1.84, with dilution of $0.59 per share to new investors. The filing reiterates clinical progress for briquilimab across CSU, CIndU and asthma studies showing rapid, deep responses and a favorable safety profile, but notes an ongoing investigation into two cohorts that showed an atypical absence of UAS7 reduction, with results expected in late 2025.